Cover Image
市場調查報告書

皮膚·軟組織感染疾病的開發中產品分析

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 257830
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
皮膚·軟組織感染疾病的開發中產品分析 Skin And Soft Tissue Infections - Pipeline Review, H1 2015
出版日期: 2015年06月30日 內容資訊: 英文 137 Pages
簡介

所謂皮膚、軟組織感染症是指在皮膚層及其下軟部組織發生的感染症。是由於皮膚因切傷、擦傷、咬傷等傷口感染了病毒、細菌或真菌而產生。主要症狀有腫脹、腫起或發燒、皮膚各處發疹、癤、癰等。主要的致病風險要素有皮膚受傷或放射線治療、血液循環不良造成體液積蓄(浮腫)、心臟衰竭、肝臟病、過去的淋巴結病史、體重過重、慢性皮膚病(例如溼疹)等。

本報告提供全球各國治療皮膚·軟組織感染疾病用的開發中產品開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

皮膚·軟組織感染疾病概要

治療藥的開發

  • 皮膚·軟組織感染疾病開發中產品:概要
  • 皮膚·軟組織感染疾病開發中產品:比較分析

各企業開發中的皮膚·軟組織治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

皮膚·軟組織治療藥:開發中的產品的一覽(各企業)

皮膚·軟組織治療藥的開發企業

  • Melinta Therapeutics, Inc
  • Wockhardt Limited
  • Atox Bio Inc.
  • Durata Therapeutics, Inc.

皮膚·軟組織:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別

藥物簡介

  • dalbavancin
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AB-103
  • WCK-2349
  • RX-04
  • 皮膚·軟組織感染疾病及社區感染型肺炎小分子
  • KBP-7072

皮膚·軟組織治療藥:開發中產品的最新趨勢

皮膚·軟組織治療藥:暫停開發的產品

皮膚·軟組織相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6488IDB

Summary

Global Markets Direct's, 'Skin And Soft Tissue Infections - Pipeline Review, H1 2015', provides an overview of the Skin And Soft Tissue Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Skin And Soft Tissue Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Skin And Soft Tissue Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Skin And Soft Tissue Infections Overview
  • Therapeutics Development
    • Pipeline Products for Skin And Soft Tissue Infections - Overview
    • Pipeline Products for Skin And Soft Tissue Infections - Comparative Analysis
  • Skin And Soft Tissue Infections - Therapeutics under Development by Companies
  • Skin And Soft Tissue Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Skin And Soft Tissue Infections - Products under Development by Companies
  • Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Atox Bio Inc.
    • Cempra, Inc.
    • CorMedix, Inc.
    • CrystalGenomics, Inc.
    • Debiopharm International S.A.
    • Dong-A Socio Group
    • GlaxoSmithKline Plc
    • Melinta Therapeutics, Inc
    • MicuRx Pharmaceuticals, Inc.
    • Motif Bio Plc
    • Nabriva Therapeutics AG
    • NovaDigm Therapeutics, Inc.
    • Phosphagenics Limited
    • Takeda Pharmaceutical Company Limited
    • Tetraphase Pharmaceuticals Inc.
    • The Medicines Company
    • Wockhardt Limited
  • Skin And Soft Tissue Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • acorafloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-7013 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ceftaroline fosamil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CG-400549 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CRMD-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1450 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1452 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fusidic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gepotidacin mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • iclaprim mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IOG-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KBP-7072 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lefamulin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-I - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NDV-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oritavancin diphosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radezolid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siderocillin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Skin Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAL-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WCK-2349 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Skin And Soft Tissue Infections - Recent Pipeline Updates
  • Skin And Soft Tissue Infections - Dormant Projects
  • Skin And Soft Tissue Infections - Discontinued Products
  • Skin And Soft Tissue Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority
      • Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections
      • Aug 05, 2014: Cubist's Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations
      • Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Cubist's SIVEXTRO (Tedizolid Phosphate) as Treatment for Serious Skin Infections
      • Feb 27, 2014: Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review
      • Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial
      • Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections
      • Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections
      • May 05, 2011: Furiex To Present Two Abstracts Featuring JNJ-Q2 At Joint Meeting Of ECCMID And ICC
      • Oct 15, 2010: Cempra To Present New Data On TAKSTA At Annual Meeting Of Infectious Diseases Society Of America
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Skin And Soft Tissue Infections, H1 2015
  • Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Development by Companies, H1 2015 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Comparative Analysis by Unknown Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Development by Companies, H1 2015 (Contd..1)
  • Skin And Soft Tissue Infections - Pipeline by Allergan Plc, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Atox Bio Inc., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Cempra, Inc., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by CorMedix, Inc., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by CrystalGenomics, Inc., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Debiopharm International S.A., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Dong-A Socio Group, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by GlaxoSmithKline Plc, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Motif Bio Plc, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Nabriva Therapeutics AG, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by NovaDigm Therapeutics, Inc., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Phosphagenics Limited, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015
  • Skin And Soft Tissue Infections - Pipeline by The Medicines Company, H1 2015
  • Skin And Soft Tissue Infections - Pipeline by Wockhardt Limited, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Skin And Soft Tissue Infections Therapeutics - Recent Pipeline Updates, H1 2015
  • Skin And Soft Tissue Infections - Dormant Projects, H1 2015
  • Skin And Soft Tissue Infections - Dormant Projects (Contd..1), H1 2015
  • Skin And Soft Tissue Infections - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Skin And Soft Tissue Infections, H1 2015
  • Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top